改良GP方案治疗晚期乳腺癌的临床观察

Clinical observation on treating metastatic breast cancer with gemcitabine combined with cisplatin

目的观察改良GP方案(吉西他滨联合顺铂)治疗晚期乳腺癌的近期疗效和不良反应。方法选取本院2012年5月至2016年1月期间收治因晚期乳腺癌患者共28例,应用吉西他滨1 000 mg/m^2,静脉滴注d1、8,顺铂25 mg/m^2,静脉滴注d1~3,每21天为1周期,每2个周期后评价疗效,获得疾病控制的患者继续化疗至6个周期。结果全组28例患者均可评价疗效,其中CR 0例,PR 10例,SD 14例,PD 4例,总有效率为35.7%。主要毒副反应为Ⅰ~Ⅱ度骨髓抑制、及Ⅰ~Ⅱ度恶心、呕吐。结论改良GP方案对晚期乳腺癌患者有一定疗效,不良反应可耐受。

Objective To evaluate the efficacy and toxicity of gemcitabine plus cisplatin in treating metastatic breast cancer which resist anthracycline and taxane. Methods Twenty- eight patients failed in anthracyeline and taxane treatment in our hospital from May 2012 to May 2016 were enrolled, then they were treated with gemcitabine 1000mg/m^2 by i.v on day one and eight, and cisplatin 25mg/m^2 by i.v on d1-3, every 21 days was one cycle. The efficacy was available every two cycles. The patients those who obtained disease control were given further chemotherapy to six cycles.Results Response and toxicity could be assessed in all the 28 patients. 0 case of CR, 10 cases of PR, 14 cases of SD,4 cases of PD. The overall response rate was 35.7%. The main adverse reaction included myelosuppression and gastrointestinal reaction.Conclusions The treatment of gemeitabine- based combined chemotherapy regimen showed good efficacy in metastatic breast cancer patients those who failed in anthracycline and taxane therapy